M. Huizing

发表

The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.

W. Tjalma, X. Trinh, K. Wouters, 2019, Biochimica et biophysica acta. Reviews on cancer.

Clinical pharmacology of carboplatin administered in combination with paclitaxel.

G. Giaccone, P. Postmus, J. Beijnen, 1997, Seminars in oncology.

Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.

G. Giaccone, O. Dalesio, P. Postmus, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients

H. Goossens, P. V. van Dam, Z. Berneman, 2021, medRxiv.

Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.

J. Schellens, H. Rosing, J. Beijnen, 2007, British journal of clinical pharmacology.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

J. Schellens, J. Beijnen, J. Schellens, 1999, British Journal of Cancer.

Tolerance of adjuvant letrozole outside of clinical trials.

B. Neyns, J. de Mey, J. Vermorken, 2008, Breast.

Taxanes: a new class of antitumor agents.

J. Beijnen, W. W. ten Bokkel Huinink, H. Pinedo, 1995, Cancer investigation.

Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel

J. Beijnen, J. Vermorken, M. Huizing, 1997 .

Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).

G. Giaccone, J. Beijnen, W. W. ten Bokkel Huinink, 1994, Seminars in oncology.

Preoperative ultrasound staging of the axilla make's peroperative examination of the sentinel node redundant in breast cancer: saving tissue, time and money.

B. X. Trinh, P. V. van Dam, M. van Goethem, 2016, European journal of obstetrics, gynecology, and reproductive biology.

The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.

W. Tjalma, O. Najim, K. Papadimitriou, 2018, European journal of obstetrics, gynecology, and reproductive biology.

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

I. Vergote, F. Amant, A. Laenen, 2015, Gynecologic oncology.

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori, M. Moroni, N. Ibrahim, 2021, Breast Cancer Research and Treatment.

Benchmarking and audit of breast units improves quality of care

P. V. van Dam, P. Vermeulen, L. Dirix, 2013, Facts, views & vision in ObGyn.

Bisphosphonates in oncology: rising stars or fallen heroes.

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2009, The oncologist.

Osteonecrosis of the jaw related to the use of bisphosphonates

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2007, Current opinion in oncology.

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

R. Laing, S. Chan, L. Fehrenbacher, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity.

E. Perez, S. Chan, J. Hamm, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

G. Giaccone, O. Dalesio, P. Postmus, 1995, Seminars in oncology.

Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.

H. Rosing, J. Beijnen, M. Huizing, 1998, Journal of chromatography. B, Biomedical sciences and applications.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck

J. Weyler, J. Vermorken, M. Huizing, 2009, BMC Cancer.

Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.

R. Rietbroek, C. Taat, D. Gouma, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy

P. Pauwels, M. Peeters, J. Hendriks, 2022, Cancers.

A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen

S. Rodenhuis, J. Schellens, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Isolation, purification and biological activity of major docetaxel metabolites from human feces.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Drug metabolism and disposition: the biological fate of chemicals.

This is a repository copy of A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line

Robin L. Jones, I. Ray-Coquard, B. Seddon, 2020 .

Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study

G. Giaccone, P. Postmus, J. Beijnen, 1996 .

Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion

S. Rodenhuis, J. Schellens, H. Rosing, 2000, Cancer Chemotherapy and Pharmacology.

Limited Sampling Models for the Pharmacokinetics of Docetaxel

A. C. Dubbelman, H. Rosing, J. Beijnen, 1997 .

Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces

J. Beijnen, A. Sparreboom, O. Tellingen, 1995, Cancer Chemotherapy and Pharmacology.

Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.

J. Beijnen, W. W. ten Bokkel Huinink, J. Vermorken, 1997, Seminars in oncology.

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.

H. Rosing, J. Beijnen, W. W. ten Bokkel Huinink, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Tuberculous mastitis presenting as a lump: a mimicking disease in a pregnant woman case report and review of literature

M. Huizing, W. Tjalma, M. Rasschaert, 2014, Acta clinica Belgica.

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.

V. Gebski, G. Kristensen, P. Witteveen, 2017, Gynecologic oncology.

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.

J. Beijnen, A. Sparreboom, O. van Tellingen, 1996, Journal of chromatography. B, Biomedical applications.

A dynamic mucin mRNA signature associates with COVID-19 disease presentation and severity

T. Breugelmans, P. Jorens, B. Loeys, 2021, JCI insight.

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome.

T. Claeys, J. Vermorken, M. Huizing, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

A. C. Dubbelman, H. Rosing, J. Beijnen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

V. Gebski, G. Kristensen, K. Lindemann, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel

J. Beijnen, O. van Tellingen, P. Willemse, 1999 .

A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin ± ifosfamide following surgery or in metastatic first line treatment (EORTC62113)

Robin L. Jones, P. Casali, I. Ray-Coquard, 2020, International Journal of Gynecological Cancer.

SARS-CoV-2 and cancer: Are they really partners in crime?

P. V. van Dam, W. Tjalma, Z. Berneman, 2020, Cancer Treatment Reviews.

Tubulin interacting agents

M. Huizing, 2006 .

Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

G. Giaccone, J. Schellens, J. Beijnen, 1998, Clinical drug investigation.

Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer

C. Rolfo, M. Peeters, K. Papadimitriou, 2015, Current Treatment Options in Oncology.

Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients

H. Goossens, P. V. van Dam, Z. Berneman, 2021, medRxiv.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

J. Schellens, J. Beijnen, L. V. van Warmerdam, 1999, Journal of Cancer Research and Clinical Oncology.

Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

S. Rodenhuis, H. Rosing, J. Beijnen, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

P. Neven, R. Bose, H. Rugo, 2021, Breast Cancer Research and Treatment.

Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma.

P. Reiss, J. Oosting, P. Brouwer, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Biobanking for Viral Hepatitis Research

S. Francque, B. D. De Winter, M. Huizing, 2019, Front. Med..

In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment

W. Tjalma, P. van Dam, S. V. van Laere, 2015, Oncotarget.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial

G. Demetri, P. LoRusso, L. Dirix, 2018, Investigational New Drugs.

1803 PEGGY: A phase II randomised study of the PI3-kinase (PI3K) inhibitor pictilisib (GDC-0941) plus paclitaxel in patients (pts) with hormone receptor (HR)-positive, HER2-negative locally recurrent or metastatic breast cancer (mBC)

R. Laing, L. Fehrenbacher, R. Roylance, 2015 .

Neoadjuvant systemic therapy in breast cancer: Challenges and uncertainties.

W. Tjalma, S. Stroobants, M. Huizing, 2017, European journal of obstetrics, gynecology, and reproductive biology.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

G. Giaccone, J. Schellens, J. Beijnen, 2000, Anti-cancer drugs.

Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study

J. Van den Brande, J. Vermorken, M. Huizing, 2010, Anti-cancer drugs.

Urinary excretion of paclitaxel and metabolites in a large series study

H. Rosing, J. Beijnen, L. V. van Warmerdam, 1998 .

Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour Infusion

H. Rosing, J. Beijnen, H. Pinedo, 1995 .

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.

E. Perez, Y. Chia, J. Hamm, 2013, The Lancet. Oncology.

The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).

P. V. van Dam, J. Weyler, W. Tjalma, 2019, Cancer treatment and research communications.

Ductal carcinoma in situ: a challenging disease

W. Tjalma, J. Vermorken, E. Marck, 2011 .

Current view on ductal carcinoma in situ and importance of the margin thresholds: A review

P. V. van Dam, W. Tjalma, K. Papadimitriou, 2014, Facts, views & vision in ObGyn.

Prognostic Significance of Oncogenic Markers in Ductal Carcinoma In Situ of the Breast: A Clinicopathologic Study

E. van Marck, J. Weyler, G. Braems, 2009, The breast journal.

The Value of the Van Nuys Prognostic Index in Ductal Carcinoma In Situ of the Breast: A Retrospective Analysis

C. Colpaert, W. Tjalma, J. Vermorken, 2007, The breast journal.

Mycosis fungoides of the vulva

W. Tjalma, Z. Berneman, O. Najim, 2020, Northern clinics of Istanbul.

Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2010, Oral oncology.

Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.

J. Van den Brande, J. Vermorken, M. Huizing, 2009, Anticancer research.

Prognostic Value of Bone Scintigraphy in Cancer Patients With Osteonecrosis of the Jaw

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2011, Clinical nuclear medicine.

Disambiguating the bisphosphonates.

J. Vermorken, M. Huizing, T. Van den Wyngaert, 2008, Annals of Oncology.

Fine Tuning of the Van Nuys Prognostic Index (VNPI) 2003 by Integrating the Genomic Grade Index (GGI): New Tools for Ductal Carcinoma In Situ (DCIS)

E. van Marck, C. Sotiriou, D. Larsimont, 2011, The breast journal.

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

W. Oyen, O. Hoekstra, E. D. de Vries, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

J. Vermorken, K. Wouters, M. Huizing, 2011, Supportive Care in Cancer.

Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests

P. V. van Dam, Z. Berneman, E. Roelant, 2021, European Journal of Cancer.

Antibody Response after BNT162B2 COVID-19 mRNA Vaccination in Cancer Patients Under Anti-Neoplastic Treatment

G. Vanhoutte, P. V. van Dam, E. Roelant, 2021, SSRN Electronic Journal.

PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).

W. Oyen, O. Hoekstra, P. Flamen, 2014 .

Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.

H. Rosing, J. Beijnen, A. Sparreboom, 1995, Journal of chromatography. B, Biomedical applications.

Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration

A. Vral, O. De Wever, S. Khelifi, 2020, Journal of clinical medicine.

Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.

W. Tjalma, K. Papadimitriou, M. Huizing, 2018, European journal of obstetrics, gynecology, and reproductive biology.

High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.

H. Rosing, J. Beijnen, H. Pinedo, 1995, Journal of chromatography. B, Biomedical applications.

A Potential Role for Fructosamine-3-Kinase in Cataract Treatment

N. Callewaert, W. Derave, M. Speeckaert, 2021, International journal of molecular sciences.

924 Pharmacology of paclitaxel (P) and metabolites in patients with altered liver function

A. Graeff, H. Rosing, J. Beijnen, 1995 .

18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies.

S. Stroobants, S. Staelens, C. Vangestel, 2022, Cancer biotherapy & radiopharmaceuticals.

Dendritic cell vaccination in malignant pleural mesothelioma: A phase I/II study.

Z. Berneman, G. Nijs, E. Smits, 2014 .

Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia

J. Beeckman, M. Speeckaert, J. Delanghe, 2023, International journal of molecular sciences.

Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

G. Broeckx, W. Tjalma, O. Najim, 2023, Frontiers in oncology.

Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

J. Van den Brande, P. Vroman, J. Vermorken, 2011, American journal of clinical oncology.

Cardiogeneticsbank@UZA: A Collection of DNA, Tissues, and Cell Lines as a Translational Tool

P. Jorens, J. Hendriks, B. Loeys, 2019, Front. Med..

Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?

J. Vermorken, M. Huizing, T. Wyngaert, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Bone Scintigraphy in Cancer Patients With Osteonecrosis of the Jaw

M. Huizing, T. Van den Wyngaert, Eric Fossion, 2011, Clinical nuclear medicine.

Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Interim results from the run-in phase of a placebo controlled randomized phase II.

A. Jager, L. Dirix, G. Jerusalem, 2017 .

Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.

A. Jager, L. Dirix, G. Jerusalem, 2018 .

Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts

P. Pauwels, S. Stroobants, S. Staelens, 2021, Molecular imaging.

Preoperative ultrasound staging of the axilla make's peroperative examination of the sentinel node redundant in breast cancer: saving tissue, time and money.

B. X. Trinh, P. V. van Dam, W. Tjalma, 2016, European journal of obstetrics, gynecology, and reproductive biology.

A clitoral verrucous carcinoma in an area of lichen planus has aggressive features

W. Tjalma, M. Huizing, V. Siozopoulou, 2017, World Journal of Surgical Oncology.

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients

J. Beijnen, J. Schellens, O. Tellingen, 1999, British Journal of Cancer.

Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.

I. Vergote, F. Amant, A. Laenen, 2015, Gynecologic oncology.

Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC)

E. Perez, J. Hamm, A. Awada, 2010 .

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.

J. Weyler, M. Huizing, D. Schrijvers, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.